85 related articles for article (PubMed ID: 15164564)
1. A deadly disease, a promising drug.
Fischman J
US News World Rep; 2004 May; 136(16):65. PubMed ID: 15164564
[No Abstract] [Full Text] [Related]
2. Cancer medicine hits a target.
Sobel RK
US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066454
[No Abstract] [Full Text] [Related]
3. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
4. Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther; 2003 Jun; 3(3):257. PubMed ID: 12820770
[No Abstract] [Full Text] [Related]
5. Approved use of gefitinib.
Lyle J
Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
[No Abstract] [Full Text] [Related]
6. Targeted therapy for non-small cell lung cancer.
Jett JR; Carr LL
Am J Respir Crit Care Med; 2013 Oct; 188(8):907-12. PubMed ID: 23721055
[TBL] [Abstract][Full Text] [Related]
7. New drug to treat most common lung cancer.
FDA Consum; 2005; 39(1):3. PubMed ID: 15818792
[No Abstract] [Full Text] [Related]
8. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
9. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
10. [Gefitinib in non-small cell lung cancer].
Nakagawa K
Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
[No Abstract] [Full Text] [Related]
11. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly R
J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
[No Abstract] [Full Text] [Related]
12. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
13. [Erlotinib. A new option for non-small cell lung cancer].
Polk B
Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
[No Abstract] [Full Text] [Related]
14. Clinical trial of Iressa.
FDA Consum; 2005; 39(2):4. PubMed ID: 16121415
[No Abstract] [Full Text] [Related]
15. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Bunn PA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5919-20. PubMed ID: 17062660
[No Abstract] [Full Text] [Related]
16. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
17. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
18. Speedy approvals for new cancer treatments.
FDA Consum; 2003; 37(4):36. PubMed ID: 12971348
[No Abstract] [Full Text] [Related]
19. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
20. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
